Pierre Gravier Sells 2,139 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) CFO Pierre Gravier sold 2,139 shares of the firm’s stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $76.95, for a total transaction of $164,596.05. Following the sale, the chief financial officer owned 90,310 shares in the company, valued at approximately $6,949,354.50. The trade was a 2.31% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

PTC Therapeutics Stock Down 0.5%

NASDAQ:PTCT traded down $0.39 during trading hours on Thursday, hitting $76.85. 1,625,361 shares of the stock traded hands, compared to its average volume of 1,684,365. The company has a market cap of $6.17 billion, a price-to-earnings ratio of 8.98 and a beta of 0.49. PTC Therapeutics, Inc. has a 1 year low of $35.95 and a 1 year high of $87.50. The stock has a 50 day moving average price of $76.26 and a 200 day moving average price of $62.43.

PTC Therapeutics (NASDAQ:PTCT) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.20 EPS for the quarter, beating the consensus estimate of ($1.19) by $1.39. PTC Therapeutics had a net margin of 42.25% and a negative return on equity of 194.11%. The firm had revenue of $211.01 million for the quarter, compared to the consensus estimate of $177.42 million. During the same period last year, the firm earned ($1.39) EPS. The company’s revenue was up 7.2% on a year-over-year basis. Equities analysts forecast that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current fiscal year.

PTC Therapeutics News Summary

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Recent fundamentals still supportive — PTC reported an earnings and revenue beat in its last quarter (Nov.) and maintains strong margins relative to peers, which underpins the stock’s valuation and analyst interest. MarketBeat PTCT profile
• Neutral Sentiment: Small inducement grant: the company approved 300 restricted stock units for a new non‑executive employee on Jan. 2 — immaterial dilution and likely not a major near‑term driver. PR Newswire: Inducement Grants
• Neutral Sentiment: Analyst consensus is a “Hold” with a mixed set of price targets and ratings — this produces limited conviction among buy‑side actors and can temper short‑term moves. Analyst consensus report
• Negative Sentiment: Heavy insider selling disclosed in multiple Form 4s — several executives and directors (including the CEO, CFO, EVP, VPs and others) sold several tens of thousands of shares across Jan. 6–7 at ~\$77 per share, representing millions of dollars of proceeds. Collective insider sales at this scale can put near‑term downward pressure on the stock and signal to some investors that insiders are taking gains. The filings and aggregated alert are here for review. InsiderTrades: Jan. insider sales alert

Hedge Funds Weigh In On PTC Therapeutics

Institutional investors have recently bought and sold shares of the business. Wellington Management Group LLP grew its stake in shares of PTC Therapeutics by 4.8% in the 3rd quarter. Wellington Management Group LLP now owns 4,918,619 shares of the biopharmaceutical company’s stock worth $301,856,000 after buying an additional 224,481 shares in the last quarter. State Street Corp lifted its holdings in shares of PTC Therapeutics by 22.1% in the 2nd quarter. State Street Corp now owns 2,996,454 shares of the biopharmaceutical company’s stock valued at $146,347,000 after acquiring an additional 541,558 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of PTC Therapeutics by 3.2% in the 2nd quarter. Geode Capital Management LLC now owns 1,934,593 shares of the biopharmaceutical company’s stock valued at $94,497,000 after acquiring an additional 60,707 shares during the last quarter. Jefferies Financial Group Inc. purchased a new position in PTC Therapeutics in the third quarter worth about $97,252,000. Finally, Palo Alto Investors LP increased its stake in PTC Therapeutics by 112.2% during the third quarter. Palo Alto Investors LP now owns 862,613 shares of the biopharmaceutical company’s stock worth $52,939,000 after acquiring an additional 456,144 shares during the last quarter.

Analyst Ratings Changes

PTCT has been the topic of several research analyst reports. Wall Street Zen upgraded PTC Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, January 3rd. Cowen reissued a “hold” rating on shares of PTC Therapeutics in a report on Wednesday, November 5th. The Goldman Sachs Group upped their price target on PTC Therapeutics from $44.00 to $50.00 and gave the stock a “sell” rating in a research note on Wednesday, November 5th. Jefferies Financial Group increased their price objective on shares of PTC Therapeutics from $63.00 to $77.00 and gave the company a “buy” rating in a report on Tuesday, October 28th. Finally, Citigroup lifted their price objective on shares of PTC Therapeutics from $50.00 to $75.00 and gave the company a “neutral” rating in a research report on Wednesday, November 5th. Nine investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $77.27.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.